Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lessened its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 18.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 42,497 shares of the biopharmaceutical company’s stock after selling 9,411 shares during the quarter. SG Americas Securities LLC’s holdings in Amicus Therapeutics were worth $400,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Wellington Management Group LLP lifted its position in shares of Amicus Therapeutics by 13.5% during the third quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock worth $255,936,000 after purchasing an additional 2,856,101 shares in the last quarter. Millennium Management LLC increased its stake in Amicus Therapeutics by 1,758.9% during the 2nd quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company’s stock worth $18,790,000 after buying an additional 1,792,277 shares during the period. Point72 Asset Management L.P. acquired a new position in Amicus Therapeutics in the 3rd quarter worth $13,530,000. Assenagon Asset Management S.A. boosted its position in Amicus Therapeutics by 141.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company’s stock valued at $21,765,000 after buying an additional 1,192,489 shares during the last quarter. Finally, Old West Investment Management LLC grew its stake in shares of Amicus Therapeutics by 617.2% during the third quarter. Old West Investment Management LLC now owns 340,441 shares of the biopharmaceutical company’s stock valued at $3,636,000 after acquiring an additional 292,976 shares in the last quarter.

Insiders Place Their Bets

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,901 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total transaction of $98,762.50. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $11,083,175. The trade was a 0.88 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts recently commented on FOLD shares. Morgan Stanley reiterated an “equal weight” rating and issued a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Monday, January 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. increased their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Amicus Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $16.88.

Amicus Therapeutics Trading Down 0.6 %

Shares of NASDAQ FOLD opened at $9.58 on Monday. Amicus Therapeutics, Inc. has a 12-month low of $8.78 and a 12-month high of $14.03. The company has a market cap of $2.86 billion, a price-to-earnings ratio of -28.18, a price-to-earnings-growth ratio of 1.54 and a beta of 0.62. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The stock’s 50 day simple moving average is $9.64 and its 200 day simple moving average is $10.47.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.